Defence

Moderna, Inc. (NASDAQ: MRNA ) reduced its position in shares of Russell Investments Group Ltd.


Russell Investments Group Ltd. reduced its stake in Moderna, Inc. (NASDAQ: MRNAGet a rating) by 13.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 88,569 shares of the company’s stock after selling 13,317 shares during the quarter. Members of Russell Investments Group Ltd. holdings in Moderna were worth $15,327,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of MRNA. Confluence Wealth Services Inc. acquired a new stake in shares of Moderna in the fourth quarter valued at $25,000. Standard Family Office LLC acquired a new stake in shares of Moderna in the fourth quarter valued at $25,000. Lake Point Wealth Management acquired a new stake in shares of Moderna in the fourth quarter valued at $27,000. IFS Advisors LLC purchased a new stake in shares of Moderna in the fourth quarter valued at $27,000. Finally, Bivin & Associates Inc. acquired a new stake in shares of Moderna in the fourth quarter valued at $29,000. Institutional investors own 61.20% of the company’s shares.

Moderna’s stock performance

Actions mRNA opened at $194.18 on Friday. The company’s 50-day moving average is $151.55, and its 200-day moving average is $152.84. Moderna, Inc. has a 52 week low of $115.61 and a 52 week high of $497.49. The company has a market cap of $77.24 billion, a PE ratio of 5.71, a PEG ratio of 0.91 and a beta of 1.61. The company has a debt-to-equity ratio of 0.04, a gearing ratio of 1.56, and a current ratio of 1.77.

Modern (NASDAQ: MRNAGet a rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, topping analysts’ consensus estimates of $4.73 by $0.51. Moderna’s net margin was 64.77% and its return on equity was 121.86%. The company had revenue of $4.73 billion for the quarter, compared to the consensus estimate of $3.95 billion. For the same period last year, earnings per share amounted to $6.46. The company’s revenue grew by 8.7% compared to the same period last year. Analysts expect that Moderna, Inc. will post 27.16 EPS for the current fiscal year.

Insider trading at Moderna

In other Moderna news, CEO Stefan Bunsel sold 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $127.13 for a total amount of $1,144,170.00. Following the completion of the sale, the chief executive officer now directly owns 5,395,535 shares in the company, valued at $685,934,364.55. The deal was disclosed in a legal filing with the Securities and Exchange Commission, which is available via this hyperlink. In other Moderna news, the president Stephen Hoge sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $168.88, for a total amount of $844,400.00. Following the completion of the sale, the president now directly owns 1,624,231 shares in the company, valued at $274,300,131.28. The deal was disclosed in a legal filing with the Securities and Exchange Commission, which is available via this hyperlink. In addition, the general manager Stefan Bunsel sold 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $127.13, for a total transaction amounting to $1,144,170.00. Following the completion of the sale, the chief executive officer now directly owns 5,395,535 shares in the company, valued at $685,934,364.55. Disclosures for this sale can be found here here. Insiders have sold 554,029 shares of company stock worth $82,263,545 over the last three months. Corporate insiders own 17.30% of the company’s shares.

Changes in analysts’ ratings

Several brokerages have recently weighed in on MRNA. SVB Leerink boosted their price objective on Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a report on Monday. Morgan Stanley cut their price objective on Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a report on Thursday. Finally, Piper Sandler cut their price objective on Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. Moderna currently has an average rating of “Hold” and a consensus target price of $226.92, according to MarketBeat.

Moderna company profile

(Get a rating)

Moderna, Inc, a biotechnology company, discovers, develops and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases in the US, Europe and abroad. . Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, endemic HCoV, and hMPV+PIV3; latent vaccines include cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus, and varicella virus vaccines; and public health vaccines consist of Zika and Nipah vaccines.

Selected stories

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)



Get news and ratings for Moderna Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Moderna and related companies. MarketBeat.com’s FREE Daily E-Newsletter.

https://www.defenseworld.net/2022/08/05/moderna-inc-nasdaqmrna-stock-position-lessened-by-russell-investments-group-ltd.html Moderna, Inc. (NASDAQ: MRNA ) reduced its position in shares of Russell Investments Group Ltd.

Back to top button